• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Aclarion Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/4/26 4:49:48 PM ET
    $ACON
    Medical Specialities
    Health Care
    Get the next $ACON alert in real time by email
    Aclarion, Inc. 8-K
    false 0001635077 0001635077 2026-06-04 2026-06-04 0001635077 ACON:CommonStockParValue0.00001PerShareMember 2026-06-04 2026-06-04 0001635077 ACON:WarrantsEachExercisableForOneShareOfCommonStockMember 2026-06-04 2026-06-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 4, 2026

     

     

     

    Aclarion, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware 001-41358 47-3324725
    (State or other jurisdiction (Commission (IRS Employer
    of incorporation) File Number) Identification No.)

     

    8181 Arista Place, Suite 100  
    Broomfield, Colorado 80021
    (Address of Principal Executive Offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (833) 275-2266

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock ACON Nasdaq Stock Market
    Common Stock Warrants ACONW Nasdaq Stock Market
    Series D Junior Participating Preferred Purchase Rights N/A Nasdaq Stock Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

       

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    On June 4, 2026, the Company held its 2026 Annual Meeting of Stockholders.

     

    The matters voted upon at the Annual Meeting and the results of such voting are set forth below.

     

     

    Proposal 1 – Election of seven directors to serve a term ending at the 2027 annual meeting, in each case until their respective successors are duly elected and qualified.

     

    Nominee   Votes For   Withheld   Broker Non-Votes
    Jeffrey Thramann   532,591   245,654   841,750
    Brent Ness   528,080   250,165   841,750
    Stephen Deitsch   532,578   245,668   841,750
    Scott Breidbart   525,005   253,240   841,750
    David Neal   468,385   309,861   841,750
    William Wesemann   528,981   249,265   841,750
    Amanda Williams   533,055   245,190   841,750

     

    All seven director nominees were duly elected.

     

     

    Proposal 2 – Ratification of appointment of independent registered accounting firm – Haynie & Company

     

    Votes For   Votes Against   Abstain   Broker Non-Votes
    1,588,388   20,623   10,985   N/A
                 

    Proposal 2 was approved.

     

     

    Proposal 3 – Approval of an amendment to our 2022 equity incentive plan

     

    Votes For   Votes Against   Abstain   Broker Non-Votes
    453,431    323,512   1,302   841,751
                 

    Proposal 3 was approved.

     

     

     

     

     2 

     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      ACLARION, INC.
         
    June 4, 2026 By: /s/ Gregory A. Gould
      Name: Gregory A. Gould
      Title: Chief Financial Officer

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     3 

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ACON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Breidbart Scott bought $18,012 worth of shares (5,664 units at $3.18) (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    5/12/26 6:53:21 PM ET
    $ACON
    Medical Specialities
    Health Care

    Director Neal David K bought $7,750 worth of shares (2,500 units at $3.10), increasing direct ownership by 125,000% to 2,502 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    5/12/26 8:30:26 AM ET
    $ACON
    Medical Specialities
    Health Care

    Chief Executive Officer Ness Brent bought $19,999 worth of shares (6,289 units at $3.18), increasing direct ownership by 57,173% to 6,300 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    5/11/26 4:30:21 PM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aclarion Rejects Echo Lake Capital's Unsolicited Acquisition Proposal

    BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today issued the following statement in response to a recent communication issued by Echo Lake Capital and its principal, Ephraim Fields. Aclarion's Board of Directors carefully reviewed Echo Lake's unsolicited public proposal and unanimously determined to reject it. The Board believes that the proposal significantly undervalues the Company and its strategic potential. Th

    6/8/26 7:05:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting

    BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that its stockholders approved all proposals at its 2026 Annual Meeting of Stockholders held on June 4, 2026. The approved proposals included the election of Jeffrey Thramann, Brent Ness, Stephen Deitsch, Scott Breidbart, David Neal, William Wesemann, and Amanda Williams to the Board of Directors to serve until the 2027 annual meeting, the ratification of

    6/8/26 7:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

    Expands availability of Nociscan in the greater Los Angeles area with leading neuroscience groupAdds to growing body of real-world evidence with study comparing chemical biomarker data from Nociscan with bone metabolic information from SPECT-CT Supports scalable growth strategy while building data assets critical to payer and provider adoption BROOMFIELD, Colo., June 03, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pai

    6/3/26 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    SEC Filings

    View All

    Aclarion Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Aclarion, Inc. (0001635077) (Filer)

    6/4/26 4:49:48 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Aclarion Inc.

    10-Q - Aclarion, Inc. (0001635077) (Filer)

    5/13/26 4:30:39 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form DEF 14A filed by Aclarion Inc.

    DEF 14A - Aclarion, Inc. (0001635077) (Filer)

    4/27/26 4:05:13 PM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Breidbart Scott bought $18,012 worth of shares (5,664 units at $3.18) (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    5/12/26 6:53:21 PM ET
    $ACON
    Medical Specialities
    Health Care

    Director Neal David K bought $7,750 worth of shares (2,500 units at $3.10), increasing direct ownership by 125,000% to 2,502 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    5/12/26 8:30:26 AM ET
    $ACON
    Medical Specialities
    Health Care

    Chief Executive Officer Ness Brent bought $19,999 worth of shares (6,289 units at $3.18), increasing direct ownership by 57,173% to 6,300 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    5/11/26 4:30:21 PM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    Financials

    Live finance-specific insights

    View All

    Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan

    BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (NASDAQ:ACON, ACONW)) ("Aclarion" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the "Rights Plan"). The Rights Plan is effective immediately and expires in one year. The Rights Plan is intended to enable all stockholders to realize the long-term value of their investment in Aclarion. The Rights Plan is also intended to reduce the likelihood that any person or group gains control of the Company without paying all stockholders an appropriate control premium. The Rights Plan will help to ensure the Board has sufficient time to

    3/19/26 9:25:40 AM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aclarion Inc.

    SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

    11/13/24 3:06:29 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Aclarion Inc.

    SC 13G - Aclarion, Inc. (0001635077) (Subject)

    9/5/24 4:19:39 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Aclarion Inc. (Amendment)

    SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

    3/29/24 5:00:57 PM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    Leadership Updates

    Live Leadership Updates

    View All

    Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting

    BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that its stockholders approved all proposals at its 2026 Annual Meeting of Stockholders held on June 4, 2026. The approved proposals included the election of Jeffrey Thramann, Brent Ness, Stephen Deitsch, Scott Breidbart, David Neal, William Wesemann, and Amanda Williams to the Board of Directors to serve until the 2027 annual meeting, the ratification of

    6/8/26 7:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan

    Commercial leader with proven track record of driving growth, surgeon adoption, and market expansion with innovative spine and surgical technologiesExpansion of commercial team reflects increasing demand for Nociscan, supported by triple-digit growth in utilization BROOMFIELD, Colo., April 28, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the appointment of Daniel Keefe as Commercial Director, Western U.S. Dan will lead commercial efforts across

    4/28/26 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

    Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion's commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the

    12/2/25 8:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care